The matricellular protein mindin induces a pro-inflammatory response in fibroblasts to manifest dermal fibrosis in scleroderma

Authors

  • Gaurav Kansagara FOM-inStem Joint Research Laboratory, Institute for Stem Cell Science and Regenerative Medicine (DBT-inStem), Bangalore, India., Manipal Academy of Higher Education, Manipal, India
  • Sunny Kataria FOM-inStem Joint Research Laboratory, Institute for Stem Cell Science and Regenerative Medicine (DBT-inStem), Bangalore, India
  • Isha Rana FOM-inStem Joint Research Laboratory, Institute for Stem Cell Science and Regenerative Medicine (DBT-inStem), Bangalore, India
  • Krithika Badarinath FOM-inStem Joint Research Laboratory, Institute for Stem Cell Science and Regenerative Medicine (DBT-inStem), Bangalore, India
  • Rania Zaarour FOM-inStem Joint Research Laboratory, Institute for Stem Cell Science and Regenerative Medicine (DBT-inStem), Bangalore, India
  • Rakesh Dey FOM-inStem Joint Research Laboratory, Institute for Stem Cell Science and Regenerative Medicine (DBT-inStem), Bangalore, India
  • Akash Gulyani Integrative Chemical Biology, Institute for Stem Cell Science and Regenerative Medicine (inStem), Bangalore, India
  • You-Wen He Department of Immunology, Duke University School of Medicine, Durham, North Carolina, USA
  • Colin Jamora FOM-inStem Joint Research Laboratory, Institute for Stem Cell Science and Regenerative Medicine (DBT-inStem), Bangalore, India

DOI:

https://doi.org/10.15305/ijir.v7i1.385

Abstract

Scleroderma, or systemic sclerosis (SSc), is a rare autoimmune and genetic disease. It is characterized by chronic inflammation and fibrosis, primarily in the skin, and progresses to internal organs, including the heart, lungs, and kidneys. While the root cause of scleroderma remains elusive, a major driver of the pathology is chronically activated fibroblasts (myofibroblasts) that excessively secret extracellular matrix (ECM) proteins. The lack of an effective treatment for scleroderma underlies the need to elucidate the molecular mechanisms of scleroderma pathogenesis that will shed new insights into potential new routes of therapeutic intervention.

Downloads

Published

14-11-2023

Issue

Vol. 7 No. 1 (2023)

Section

Abstracts

License

Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Indian journal of Inflammation Research’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJIR, as it can lead to productive exchanges, as well as earlier and greater citation of published work.